Hepatobiliary Disposition

Evaluate accumulation, clearance, and DDI risk in hepatocytes.

In Vitro Modeling with B-CLEAR® Technology

Quantify Hepatic Uptake, Intracellular Concentration, and Biliary Transport to Assess DDI Risk

Using B-CLEAR® technology we design and implement in vitro hepatocyte models to predict and quantitate hepatic uptake, intracellular concentration, basolateral and biliary disposition, DDIs, and other interaction effects.

Disposition Evaluation Studies

In vitro disposition evaluation studies quantitate biliary disposition of test articles and metabolites using B-CLEAR technology.

Disposition DDI Studies

In vitro disposition DDI studies assess efflux DDI using B-CLEAR technology.

Individual Studies or As Part of Integrated Programs

We implement programs to predict transporter-mediated hepatic disposition pharmacokinetics including:

  • Hepatobiliary disposition, including uptake and biliary clearance

  • Intracellular concentration (ICC)

  • Fraction metabolized, and disposition of the metabolite(s)

  • Efflux DDIs

Assessment Programs to Answer Critical Research Questions

Data from our in vitro hepatic disposition models is used to guide SAR development, understand mechanisms of uptake and disposition, inform lead selection decisions and clinical program strategies, address regulatory concerns, evaluate transporter-based interactions.

Answer Clearance Questions Through the R&D Process

From discovery through regulatory submissions, we offer customized assessment programs to help our clients answer critical research questions about their compounds:

  • Does the test article get into the liver?

  • What are the mechanisms of metabolism and disposition?

  • Which analogs offer favorable disposition properties?

  • Does hepatic clearance vary across species?

  • What is the potential for in vivo hepatic accumulation and biliary clearance?

  • Will a compound impact hepatic transporter function?

  • Is there risk for transporter-based drug-drug interactions?